Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

LAIV H5N2

2 doses provided intranasally

OTHER

Placebo

2 doses of placebo provided intranasally

Trial Locations (1)

197376

Research Institute of Influenza, Saint Petersburg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Microgen

OTHER

collaborator

Institute of Experimental Medicine, Russia

OTHER

lead

PATH

OTHER